Table 1 Basic characteristics of patients with NCRNNELM
Characteristics | N (%) |
|---|---|
Patients (number) | 114 |
Sex: female | 90 (78%) |
Age (years), median[range], > 60 years) | 55[26–83], 37% |
BMI mean (range) | 24.6 (16.8–38.7) |
ASA 1–2 | 89 (78.1%) |
Primary tumor sites | |
Breast | 70 (61%) |
Genito-urinary | 13 (11%) |
Gastro-intestinal | 10 (9%) |
Sarcoma | 11 (10%) |
Melanoma | 4 (4%) |
Squamous | 3 (3%) |
Others | 3 (3%) |
Primary lymph node metastasis | 46 (40%) |
Timing of diagnosis | |
0–12 months | 43 (38%) |
12–24 months | 13 (11%) |
> 24 months | 58 (51%) |
Number of nodules mean (median[range]) | 1.86 [1 (1–9)] |
Multi-nodular | 62 (54%) |
Size of largest nodule mean (median[range]) (mm) | 32.85[25 (2–70)] |
Size > 50 mm | 23 (20%) |
Systemic treatment for the primary tumor | |
NACT | 42 (37%) |
ACT | 79 (69%) |
Hormonal therapy | 56 (49%) |
Radiotherapy | 55 (48%) |
Trastuzumab | 25 (22%) |
Glivec | 9 (8%) |
Other | 3 (3%) |
Systemic treatment for liver metastases | |
NACT | 95 (83%) |
ACT | 66 (58%) |
Type of surgery | |
Open approach/laparoscopy | 79 (69%)/35 (31%) |
RF | 33 (29%) |
Major hepatectomy | 23 (20%) |
Complications Clavien-Dindo | |
0 | 91 (80%) |
I–II | 10 (9%) |
III (a-b) | 12 (11%) |
IV | 1 (1%) |
V | 0 |
Relapse | 65 (57%) |
Liver | 37 (33%) |
Liver + lung | 3 (3%) |
Liver + bone | 3 (3%) |
Liver + brain | 2 (2%) |
Liver + peritoneum | 3 (3%) |
Lung | 4 (4%) |
Peritoneum | 3 (3%) |
Bone | 1 (1%) |
Brain | 1 (1%) |
Multiple | 8 (7%) |
Number of hepatectomies | |
2 | 11 (10%) |
3 | 1 (1%) |
AFC score | |
1 | 16 (14%) |
2 | 19 (17%) |
3 | 33 (29%) |
4 | 25 (22%) |
5 | 16 (14%) |
6 | 5 (4%) |
Low/ Intermediate risk AFC score | 68 (60%)/46 (40%) |
mCRS | |
0 | 24 (21%) |
1 | 38 (33%) |
2 | 26 (23%) |
3 | 23 (20%) |
4 | 3 (3%) |
Low-/high-risk (0–2) | 88 (77%)/26 (23%) |